Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in hepatocellular carcinoma

Wu,Wen-Yong; Li,Jun; Wu,Zheng-Sheng; Zhang,Chang-Le; Meng,Xiang-Ling; Lobie,Peter  E.

doi:10.3892/etm.2011.254

Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in hepatocellular carcinoma

Authors:
- Wen-Yong Wu
- Jun Li
- Zheng-Sheng Wu
- Chang-Le Zhang
- Xiang-Ling Meng
- Peter E. Lobie
View Affiliations

Affiliations: School of Pharmacy, Anhui Medical University, Hefei, Anhui 230032, P.R. China, School of Pharmacy, Anhui Medical University, Hefei, Anhui 230032, P.R. China, Department of Pathology, Anhui Medical University, Hefei, Anhui 230032, P.R. China, Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P.R. China, Cancer Science Institute of Singapore and Department of Pharmacology, National University of Singapore, Singapore
Published online on: April 11, 2011 https://doi.org/10.3892/etm.2011.254
Pages: 647-653

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Altered expression of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and suppressor of cytokine signaling 3 (SOCS3) has been implicated in various types of human cancers. However, the clinical role of pSTAT3 and SOCS3 in hepatocellular carcinoma (HCC) is not well established. Immunohistochemical analysis of pSTAT3, SOCS3, Ki67 and VEGF expression was performed on tissue microarrays from 138 HCC patients. The expression of STAT3 mRNA was further detected by in situ hybridization. The association of pSTAT3 and SOCS3 expression with clinicopathological factors and patient survival was analyzed. Altered expression of pSTAT3 and SOCS3 was observed in HCC specimens, compared to adjacent non-tumor tissue. Increased expression of pSTAT3 was correlated with large tumor size, higher clinical stage, Ki67 and VEGF expression, as well as poor patient survival. Decreased expression of SOCS3 was correlated with the expression of Ki67, VEGF and pSTAT3, and poor patient survival. Moreover, the expression of pSTAT3 was conversely correlated with SOCS3 expression in HCC. Our results indicate that deregulated expression of pSTAT3 and SOCS3 may play roles in the development and progression of HCC. PSTAT3 and SOCS3 should be further evaluated as potential novel biomarkers for HCC prognosis.

View Figures

View References

1.	He J, Gu D, Wu X, et al: Major causes of death among men and women in China. N Engl J Med. 353:1124–1134. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Hirano T, Ishihara K and Hibi M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 19:2548–2556. 2000. View Article : Google Scholar : PubMed/NCBI
3.	Valentino L and Pierre J: JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol. 71:713–721. 2006. View Article : Google Scholar : PubMed/NCBI
4.	Buettner R, Mora LB and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 8:945–954. 2002.PubMed/NCBI
5.	Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
6.	Yu H and Jove R: The STATs of cancer – new molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
7.	Kanda N, Seno H, Konda Y, et al: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 23:4921–4929. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Choi JH, Ahn MJ, Park CK, Han HX, Kwon SJ, Lee YY and Kim IS: Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray. APMIS. 114:619–625. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Yang SF, Wang SN, Wu CF, Yeh YT, Chai CY, Chunag SC, Sheen MC and Lee KT: Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J Clin Pathol. 60:642–648. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Deng JY, Sun D, Liu XY, Pan Y and Liang H: STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol. 16:5380–5387. 2010. View Article : Google Scholar : PubMed/NCBI
11.	Kim HS, Park YH, Lee J, Ahn JS, Kim J, Shim YM, Kim JH, Park K, Han J and Ahn MJ: Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. Cancer. 116:676–685. 2010. View Article : Google Scholar
12.	Huang WT, Yang SF, Wu CC, Chen WT, Huang YC, Su YC and Chai CY: Expression of signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 in urothelial carcinoma. Kaohsiung J Med Sci. 25:640–646. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Kile BT and Alexander WS: The suppressors of cytokine signalling (SOCS). Cell Mol Life Sci. 58:1627–1635. 2001. View Article : Google Scholar : PubMed/NCBI
14.	Bai L, Yu Z, Qian G, Qian P, Jiang J, Wang G and Bai C: SOCS3 was induced by hypoxia and suppressed STAT3 phosphorylation in pulmonary arterial smooth muscle cells. Respir Physiol Neurobiol. 152:83–91. 2006. View Article : Google Scholar : PubMed/NCBI
15.	O’Shea JJ, Gadina M and Schreiber RD: Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 109:S121–S131. 2002.PubMed/NCBI
16.	Edmondson HA and Steiner PE: Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
17.	Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F and Xu XC: Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 122:2050–2056. 2008. View Article : Google Scholar : PubMed/NCBI
18.	Wu ZS, Wu Q, Wang CQ, Wang XN, Wang Y, Zhao JJ, Mao SS, Zhang GH, Zhang N and Xu XC: MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis. BMC Cancer. 10:5422010. View Article : Google Scholar : PubMed/NCBI
19.	Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, Smits R, Xia B, Kuipers EJ and van der Woude CJ: Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut. 59:227–235. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Brown DC and Gatter KC: Ki67 protein: the immaculate deception? Histopathology. 40:2–11. 2002. View Article : Google Scholar
21.	Yang SF, Yeh YT, Wang SN, Hung SC, Chen WT, Huang CH and Chai CY: SOCS-3 is associated with vascular invasion and overall survival in hepatocellular carcinoma. Pathology. 40:558–563. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Niu G, Wright KL, Huang M, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
23.	Alexander WS and Hilton DJ: The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol. 22:503–529. 2004. View Article : Google Scholar : PubMed/NCBI
24.	Yoshimura A, Nishinakamura H, Matsumura Y and Hanada T: Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther. 7:100–110. 2005. View Article : Google Scholar : PubMed/NCBI
25.	He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F and Jablons DM: SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA. 100:14133–14138. 2003. View Article : Google Scholar : PubMed/NCBI
26.	Yu ZB, Bai L, Qian P, Xiao YB, Wang GS, Qian GS, Bai CX and Min JX: Restoration of SOCS3 suppresses human lung adenocarcinoma cell growth by downregulating activation of Erk1/2, Akt apart from STAT3. Cell Biol Int. 33:995–1001. 2009. View Article : Google Scholar : PubMed/NCBI
27.	Croker BA, Krebs DL, Zhang JG, et al: SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol. 4:540–545. 2003. View Article : Google Scholar : PubMed/NCBI
28.	Ying M, Li D, Yang L, Wang M, Wang N, Chen Y, He M and Wang Y: Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma. J Cancer Res Clin Oncol. 136:1617–1626. 2010. View Article : Google Scholar : PubMed/NCBI
29.	Nakagawa T, Iida S, Osanai T, Uetake H, Aruga T, Toriya Y, Takagi Y, Kawachi H and Sugihara K: Decreased expression of SOCS-3 mRNA in breast cancer with lymph node metastasis. Oncol Rep. 19:33–39. 2008.PubMed/NCBI
30.	Sakai I, Takeuchi K, Yamauchi H, Narumi H and Fujita S: Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood. 100:2926–2931. 2002. View Article : Google Scholar : PubMed/NCBI
31.	Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen AM, Geisler C, Wasik M and Ødum N: Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia. 19:209–213. 2005. View Article : Google Scholar : PubMed/NCBI